CDC-RFA-PS22-2204: Enhancing National STD/HIV Prevention Efforts by Promoting Holistic, Comprehensive and Evidence-Informed, Health and Wellness Approaches through Strategic Partnerships
Closed
This grant is closed. A newer notice from the same program is forecast: Holistic and Evidence-Informed Wellness for STI Prevention (CDC-RFA-PS-27-0237). Status: Expected deadline May 31, 2027. It is in our archive of Centers for Disease Control - NCHHSTP notices from 2022.
Centers for Disease Control - NCHHSTP offered grants to any type of organization. It expected to make one award worth $3.0 million in total. Applications closed on April 19, 2022.
From the official notice on Grants.gov, last changed March 8, 2022. Checked November 7, 2026.
- Total funding$3.0 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | February 18, 2022 |
|---|---|
| Deadline | April 19, 2022 |
| Archived by Grants.gov | May 19, 2022 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
This program is authorized under Sections 301 and 318(b) of the Public Health Service Act; 42 U.S.C. Sections 241 and 247c(b). Domestic institutions or organizations are eligible to apply. Foreign institutions are not eligible to apply. An individual is not eligible to apply for this cooperative agreement.
Is this a realistic fit?
- Most of the program's money (50% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This FOA will provide support to the National Coaltion for Sexual Health (NCSH) (http://nationalcoalitionforsexualhealth.org/). The Coalition brings together national leadership in order to accelerate STD/HIV prevention by advancing a more holistic and integrated public health approach by focusing on health and wellness frameworks, including sexual health in the U.S. These efforts represent an attempt to supplement traditional, disease-specific prevention frameworks with one emphasizing the broader promotion of health and wellness, including sexual health. The NCSH aims to improve sexual health and well-being by encouraging productive and sustained conversations about sexual health and promoting high quality sexual health information and health services. In addition to STD/HIV prevention, adopting such a holistic health and wellness-based approach is pertinent to a number of public health priorities, including: prevention and control of viral hepatitis; improved reproductive health, including teen and unplanned pregnancy prevention; and prevention of sexual and intimate partner violence. The Coalition will continue to build a nationally-representative Coalition of members from a diverse range of entities important to enhancing STD/HIV prevention, as well as maintain, lead, organize and facilitate the established group of partners who currenlty make up the Coalition. The Coalition will continue implementation of programmatic and evaluation activities, communication activities including dissemination and promotion of Coalition products, maintain and update Coalition websites and continue to convene Coalition action groups in order to leverage the work of the Coalition to advance sexual health. Lastly, the Coalition will sustain the momentum achieved through Coalition activities to enhance STD/HIV prevention and improve sexual health at a national level.
Who has won Sexually Transmitted Diseases (STD) Provider Education Grants grants before
From fiscal 2021 to 2025, Sexually Transmitted Diseases (STD) Provider Education Grants (93.978) awarded $50.4 million across 21 grant awards, an average of $2.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Denver Health and Hospital Authority | Colorado | 2 | $7.8 million |
| The Regents of the University of California, San Francisco | California | 3 | $6.6 million |
| University of Washington | Washington | 1 | $6.4 million |
| Altarum Institute | Michigan | 2 | $5.5 million |
| The Trustees of Columbia University in the City of New York | New York | 1 | $3.2 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-PS-27-0237, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-PS22-2204 still open?
No. It closed on April 19, 2022. A newer notice is forecast: CDC-RFA-PS-27-0237, expected deadline May 31, 2027.
Who can apply for Enhancing National STD/HIV Prevention Efforts by Promoting Holistic, Comprehensive and Evidence-Informed, Health and Wellness Approaches through Strategic Partnerships?
Centers for Disease Control - NCHHSTP accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Enhancing National STD/HIV Prevention Efforts by Promoting Holistic, Comprehensive and Evidence-Informed, Health and Wellness Approaches through Strategic Partnerships?
Closed April 19, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $3.0 million in total for one award.
Who has won Sexually Transmitted Diseases (STD) Provider Education Grants grants before?
The largest recipients over five fiscal years were Denver Health and Hospital Authority, The Regents of the University of California, San Francisco, University of Washington. The program made 21 awards worth $50.4 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)